Randomised phase III trial of docetaxel +/- GVAX
Location of trial: Cambridge, Clatterbridge, Guildford, Hammersmith, Hull, Leeds, Manchester, Mount Vernon, Nottingham, Preston, Royal Marsden
Start date for recruitment: 2006
End date for recruitment: 2009
Number of men being recruited: 600
Aim of the trial
To determine whether the addition of GVAX immunotherapy improves survival in men receiving chemotherapy with docetaxel for advanced disease
Criteria for inclusion in trial
You can enter this trial if you:
-
1. have metastatic disease (cancer that has spread to other parts of the body),
2. have hormone refractory disease (where hormone therapy has stopped working),
3. are taking pain medication and
4. have not had chemotherapy with docetaxel
What does the trial involve?
Men on the trial all receive standard chemotherapy with docetaxel every three weeks. Men will be allocated either to receive chemotherapy alone, or to receive GVAX in addition. GVAX is given by injections, every three weeks, two days after the chemotherapy. Men will have scans every 12 weeks to assess their response. They will receive up to ten chemotherapy treatments over 30 weeks.
For further information, contact
Ruth Woode-Amissah
Email: ruth.woode-amissah@rmh.nhs.uk
Telephone: 0208 661 3070
Return to the list of current research studies